The acceptability of the risk of death in the treatment of respiratory diseases in France.

IF 2.7 3区 经济学 Q1 ECONOMICS
Caroline Orset
{"title":"The acceptability of the risk of death in the treatment of respiratory diseases in France.","authors":"Caroline Orset","doi":"10.1186/s13561-024-00541-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The costs associated with respiratory illnesses in the French healthcare budget continue to rise. However, pharmaceutical companies and research centres are continuously developing new treatments. Consequently, accepting these treatments, which necessitates the acceptance of the mortality risk associated with their use, represents a significant economic and public health issue. Our study aims to assess this acceptance.</p><p><strong>Methods: </strong>The data were obtained from an online questionnaire completed by 315 respondents located in France during June and July 2019. The standard gamble method was employed to ascertain the acceptability of risk. This method quantifies the 'disutility' of a health state by evaluating the extent to which an individual is willing to accept a specific mortality risk in exchange for avoiding the state.</p><p><strong>Results: </strong>The study demonstrated that individuals, irrespective of their personal characteristics, were willing to accept a treatment with an average mortality risk of less than 19%. The findings revealed discrepancies between individuals' perceptions of mortality and actual risks.</p><p><strong>Conclusions: </strong>In France, it is incumbent upon public decision-makers and research centres to ensure that treatment-related mortality rates remain below 19% so that patients readily accept treatment, irrespective of their personal characteristics. In addition, they should provide further information on the risks associated with treating respiratory diseases to avoid a discrepancy between the mortality risks perceived by individuals and the actual risks.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"78"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443873/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Economics Review","FirstCategoryId":"96","ListUrlMain":"https://doi.org/10.1186/s13561-024-00541-3","RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The costs associated with respiratory illnesses in the French healthcare budget continue to rise. However, pharmaceutical companies and research centres are continuously developing new treatments. Consequently, accepting these treatments, which necessitates the acceptance of the mortality risk associated with their use, represents a significant economic and public health issue. Our study aims to assess this acceptance.

Methods: The data were obtained from an online questionnaire completed by 315 respondents located in France during June and July 2019. The standard gamble method was employed to ascertain the acceptability of risk. This method quantifies the 'disutility' of a health state by evaluating the extent to which an individual is willing to accept a specific mortality risk in exchange for avoiding the state.

Results: The study demonstrated that individuals, irrespective of their personal characteristics, were willing to accept a treatment with an average mortality risk of less than 19%. The findings revealed discrepancies between individuals' perceptions of mortality and actual risks.

Conclusions: In France, it is incumbent upon public decision-makers and research centres to ensure that treatment-related mortality rates remain below 19% so that patients readily accept treatment, irrespective of their personal characteristics. In addition, they should provide further information on the risks associated with treating respiratory diseases to avoid a discrepancy between the mortality risks perceived by individuals and the actual risks.

法国呼吸系统疾病治疗中死亡风险的可接受性。
背景:法国医疗预算中与呼吸系统疾病相关的费用持续上升。然而,制药公司和研究中心正在不断开发新的治疗方法。因此,接受这些治疗方法就必须接受与使用这些治疗方法相关的死亡风险,这是一个重大的经济和公共卫生问题。我们的研究旨在评估这种接受程度:数据来自 2019 年 6 月至 7 月期间法国 315 名受访者填写的在线问卷。我们采用了标准赌博法来确定风险的可接受性。该方法通过评估个人愿意接受特定死亡风险以换取避免健康状况的程度,来量化健康状况的 "无用性":研究表明,无论个人特征如何,他们都愿意接受平均死亡风险低于 19% 的治疗方法。研究结果表明,个人对死亡率的认识与实际风险之间存在差异:在法国,公共决策者和研究中心有责任确保与治疗相关的死亡率保持在 19% 以下,从而使患者无论其个人特征如何,都愿意接受治疗。此外,他们还应该提供更多关于治疗呼吸系统疾病相关风险的信息,以避免个人认为的死亡率风险与实际风险之间的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
4.20%
发文量
59
审稿时长
13 weeks
期刊介绍: Health Economics Review is an international high-quality journal covering all fields of Health Economics. A broad range of theoretical contributions, empirical studies and analyses of health policy with a health economic focus will be considered for publication. Its scope includes macro- and microeconomics of health care financing, health insurance and reimbursement as well as health economic evaluation, health services research and health policy analysis. Further research topics are the individual and institutional aspects of health care management and the growing importance of health care in developing countries.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信